Effects of ZnT8 on epithelial-to-mesenchymal transition and tubulointerstitial fibrosis in diabetic kidney disease

Xiuli Zhang1,2, Tingwen Guan2, Boxuan Yang2, Harvest F. Gu3 and Zhihong Chi2

Abstract
Zinc transporter 8 (ZnT8) transports zinc ions for crystallization and storage of insulin in pancreatic beta-cells and ZnT8 dysfunction is involved in pathogenesis of diabetes. The current study aimed to investigate whether ZnT8 has effects in pathophysiology of diabetic kidney disease (DKD) by using animal models for diabetes, including STZ-induced diabetic, db/db, ZnT8-KO, ZnT8-KO-STZ and ZnT8-KO-db/db mice. Results demonstrated that urine albumin to creatinine ratio and epithelial-to-mesenchymal transition (EMT) were increased in kidneys of ZnT8-KO-STZ and ZnT8-KO-db/db mice compared with C57BL/6J and ZnT8-KO mice, while serum TGF-β1, IL-6, and TNF-α levels were elevated in parallel. In kidneys of mice intercrossed between ZnT8-KO and STZ-induced diabetic or db/db mice, these three inflammatory factors, ACR and EMT were also found to be increased compared with C57BL/6J, db/db and ZnT8-KO mice. Furthermore, ZnT8 up-regulation by hZnT8-EGFP reduced the levels of high glucose (HG)-induced EMT and inflammatory factors in normal rat kidney tubular epithelial cell (NRK-52E cells). Expression of phosphorylated Smad2/Smad3 was up-regulated after HG stimulation and further enhanced by ZnT8 siRNA but down-regulated after hZnT8-EGFP gene transfection. The current study thus provides the first evidence that ZnT8 protects against EMT-tubulointerstitial fibrosis though the restrain of TGF-β1/Smads signaling activation in DKD.

Introduction
Diabetic kidney disease (DKD, previously termed as diabetic nephropathy) is the most common cause of chronic kidney failure and end stage kidney disease. Clinical manifestation of DKD is characterized by hyperfiltration, renal hypertrophy, progressively increasing proteinuria, and deterioration of renal function. Loss of podocytes, enhanced glomerular and tubulointerstitial accumulation of extracellular matrix (ECM), apoptosis of renal tubular epithelial cells, infiltration of blood mononuclear cells, and proliferation of interstitial mesenchymal cells are the principal pathological features of DKD, which has been detected in renal biopsy samples from patients with DKD. Tubulointerstitial fibrosis is the final common pathway of the majority of chronic progressive renal diseases, including DKD, which involves expansion of interstitial fibroblasts, myofibroblast activation and ECM accumulation, leading to the loss of normal kidney function and, ultimately, renal failure. EMT of mature tubular epithelial cells appears as the central point in the early pathogenesis of the development and progression of renal interstitial fibrosis in DKD. The character is that epithelial cells lose their epithelial specific markers, undergo cytoskeletal remodeling, and gain a mesenchymal phenotype. Furthermore, accumulating evidence has demonstrated that inflammatory molecules and mediators...
are important in the pathogenesis of DKD. Several inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and transforming growth factor beta 1 (TGF-β1) are found to be associated with glomerular and tubulointerstitial damage in the progresses of DKD17–20.

Zinc transporter 8 (ZnT8 also known as SLC30A8) is localized in insulin secretory granules in the islets of Langerhans and facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles in pancreatic beta-cells. Recently, we have reported that ZnT8 also transports zinc into Leydig cell mitochondria with gonadotropin stimulation and plays a role in testosterone production via the PKA signaling pathway. ZnT8 has genetic, epigenetic and biological effects in the pathogenesis of diabetes. ZnT8 auto-antibodies (ZnT8A) are considered as the most recently discovered and least-characterized islet auto-antibodies to predict risk of future type 1 diabetes (T1DM) and type 2 diabetes (T2DM). Genetic association studies, including ours have demonstrated that the common single nucleotide polymorphisms in the SLC30A8 gene confer the risk susceptibility to type 2 diabetes (T2DM), while the rare loss-of-function variants in the gene have protective effects in the disease. An epigenetic study from our group has reported that increased DNA methylation of the SLC30A8 gene promoter is associated with T2DM.

In the current study, we initially designed and performed in vivo experiments with non-diabetic control, ZnT8-KO, STZ-induced (animal model for T1DM) and ZnT8-KO-STZ mice and then with db/db (animal model for T2DM) and ZnT8-KO-db/db mice. We further carried out in vitro experiments with high glucose (HG)-stimulated EMT in normal rat kidney tubular epithelial cell (NRK-52E cells) by using transfection and RNA interference (RNAi) protocols. The aims were to explore the effects of ZnT8 on EMT-tubulointerstitial fibrosis in DKD and to understand its underlying molecular mechanism.

Results

Metabolic and biochemical parameters in the studied mice

STZ-induced diabetic mouse is an animal model for T1DM. In the initial experiments, ZnT8-KO, STZ-induced and ZnT8-KO-STZ diabetic mice were studied. As seen in Table 1A, compared with non-diabetic control (C57BL/6J) and ZnT8-KO mice, STZ-induced diabetic and ZnT8-KO-STZ mice were found to be exhibited diabetic symptoms such as increase in diet, drink and urine while body weight loss. Fasting blood glucose (FBG) levels in STZ-induced and ZnT8-KO-STZ diabetic mice were significantly higher than controls. After injection of STZ for 16 weeks, blood serum creatinine (Cr), urea nitrogen (BUN) and urine albumin-to-creatinine ratio (UACR) were increased in STZ-induced and ZnT8-KO-STZ diabetic mice, while ZnT8-KO-STZ mice exhibited the highest Cr, BUN and UACR levels among the groups.

Db/db mouse is another animal model and for T2DM. The next experiments with Control, ZnT8-KO, db/db and ZnT8-KO-db/db mice were done. In Table 1B, db/db and ZnT8-KO-db/db mice exhibited significantly increased levels of not only FBG but also body weight compared with control and ZnT8-KO mice, while db/db and ZnT8-KO-db/db mice demonstrated higher BUN, Cr and UACR than what in control and ZnT8-KO mice. In both initial and next experiments, the comparison analyses between control and ZnT8-KO mice were performed and no significant difference between control and ZnT8-KO mice was seen.

Serum levels of TGF-β1, IL-6 and TNF-α in the studied mice

Serum levels of TGF-β1, IL-6 and TNF-α in all studied mice were analyzed with Elisa protocols in initial and next experiments, respectively, and data were included in Table 1A, B. Serum levels of TGF-β1, IL-6 and TNF-α in STZ-induced diabetic, db/db, ZnT8-KO-STZ and ZnT8-KO-db/db mice were significantly elevated compared with control or ZnT8-KO mice, while these three inflammatory factors had similar levels in ZnT8-KO-STZ and ZnT8-KO-db/db mice.

Effects of ZnT8 in EMT-tubulointerstitial fibrosis on kidneys of the studied mice

To investigate the effect of ZnT8 in EMT-tubulointerstitial fibrosis in kidneys, expression and localization of anti-aquaporin-1 (APQ1, a proximal tubule marker) and Vimentin (a mesenchymal marker) and E-cadherin (E-ca, an epithelial specific marker) in renal interstitium of control, STZ-induced and ZnT8-KO-STZ diabetic mice were detected by using the double-immunofluorescence staining in the initial experiments. Figure 1a implicated that Vimentin protein (red) was virtually absent in kidneys of control mice or ZnT8-KO mice (Fig. 1a, a1–3, b1–3) compared with STZ-induced
and ZnT8-KO-STZ diabetic mice. Furthermore, the intensity of Vimentin staining in interstitial compartment of ZnT8-KO-STZ diabetic mice (Fig. 1a, d1–3) was stronger than what in STZ-induced diabetic mice (Fig. 1a, c1–3). Unlike expression of Vimentin, expression of E-cadherin of the tubular epithelial cells in kidneys of STZ-induced and ZnT8-KO-STZ diabetic mice was decreased compared with control mice or ZnT8-KO mice (Fig. 1b, a1–d3). Consistently, analyses of kidney tissues by Western blot showed that expression levels of Vimentin were significantly increased but E-cadherin decreased in kidneys of ZnT8-KO-STZ mice compared to control or ZnT8-KO mice (Fig. 1c).

In next experiments, the similar analyses were further conducted in control, db/db and ZnT8-KO-db/db mice and the results were represented in Fig. 2a–c. Similarly, Vimentin expression was found to be increased while E-cadherin expression decreased in kidneys from db/db and ZnT8-KO-db/db mice.

**Effects of ZnT8 on HG-induced EMT-tubulointerstitial fibrosis in NRK-52E cells**

To understand the mechanism underlying the effect of ZnT8 in EMT-tubulointerstitial fibrosis in kidneys of the studied mice, the experiments for HG-stimulated on EMT by modulating ZnT8 expression in NRK-52E cells were further performed with transfection protocol combined with RNAi techniques. The highest expression levels of ZnT8 after transfection of hZnT8-EGFP was found at 72 h (Supplemental Fig. 1). We confirmed that ZnT8 protein expression was reduced to ~13% of the normal level by using Western blotting analyses after ZnT8siRNA transfection (Supplementary Fig. 1).

After transfection of hZnT8-pcDNA3.1/myc-HisA or ZnT8-siRNA, the NRK-52E cells were then treated with HG for 48 h. To evaluate the effects of ZnT8 on Zinc distribution, we performed TSQ fluorescence staining in the cells. A strong granular zinc staining was found in the perinuclear region of hZnT8 and HG/hZnT8 groups.

---

**Table 1** (A) Metabolic and biochemical parameters in Control, ZnT8-KO, STZ-induced and ZnT8-KO-STZ diabetic mice; (B) Metabolic and biochemical parameters in Control, ZnT8-KO, db/db and ZnT8-KO-db/db mice.

| A | Cont | ZnT8-KO | STZ-induced | ZnT8-KO-STZ |
|---|------|---------|-------------|-------------|
| FBG (mM) | 5.21 ± 0.23 | 5.98 ± 0.17 | 23.48 ± 4.29** | 26.75 ± 5.11** |
| Body weight (g) | 26.3 ± 1.22 | 27.2 ± 2.31 | 21.06 ± 2.67* | 22.32 ± 2.39* |
| Kidney weight (g) | 0.32 ± 0.07 | 0.34 ± 0.26 | 0.33 ± 0.05 | 0.33 ± 0.06 |
| BUN (mM) | 6.23 ± 0.62 | 6.98 ± 0.43 | 23.37 ± 5.04** | 25.09 ± 7.23** |
| Cr (µM) | 27.12 ± 3.79 | 28.30 ± 3.25 | 79.36 ± 7.98** | 80.03 ± 8.46** |
| UACR (µg/mg) | 19.9 ± 2.03 | 21.32 ± 2.39 | 223.90 ± 10.78** | 269.70 ± 11.36** |
| TGF-β1 (pg/ml) | 1.94 ± 0.43 | 1.89 ± 0.20 | 4.46 ± 0.75** | 8.85 ± 0.95** |
| IL-6 (pg/ml) | 2.63 ± 0.41 | 2.82 ± 0.44 | 5.77 ± 0.88** | 6.84 ± 0.96** |
| TNF-α (pg/ml) | 9.37 ± 1.01 | 9.58 ± 0.65 | 29.71 ± 1.67** | 42.97 ± 2.15** |

| B | Cont | ZnT8-KO | db/db | ZnT8-KO-db/db |
|---|------|---------|-------|--------------|
| FBG (mM) | 5.19 ± 0.18 | 5.71 ± 0.12 | 39.70 ± 2.62** | 43.90 ± 4.21**† |
| Body weight (g) | 25.7 ± 1.09 | 26.5 ± 2.03 | 43.10 ± 2.33* | 44.27 ± 3.06* |
| Kidney weight (g) | 0.32 ± 0.09 | 0.33 ± 0.13 | 0.34 ± 0.09 | 0.34 ± 0.11 |
| BUN (mM) | 5.31 ± 0.19 | 5.62 ± 0.22 | 10.79 ± 0.19** | 13.01 ± 8.32**† |
| Cr (µM) | 12.78 ± 1.98 | 13.15 ± 1.94 | 68.46 ± 9.17** | 92.38 ± 10.35**† |
| UACR (µg/mg) | 9.91 ± 0.92 | 11.32 ± 1.39 | 308.63 ± 2.29** | 357.46 ± 13.17**† |
| TGF-β1 (pg/ml) | 1.97 ± 0.12 | 1.91 ± 0.17 | 5.03 ± 0.83** | 7.02 ± 0.69**‡ |
| IL-6 (pg/ml) | 2.91 ± 0.36 | 3.19 ± 0.35 | 7.39 ± 0.36** | 6.87 ± 0.72**‡ |
| TNF-α (pg/ml) | 10.21 ± 1.02 | 9.34 ± 0.83 | 29.27 ± 2.29** | 39.77 ± 1.76**‡ |

Data are presented as means ± SEM.

*P < 0.05 and **P < 0.01 vs. Control group; †P < 0.05 and **P < 0.01 vs. STZ-induced diabetic group. Mice in each group, n = 8.

*P < 0.05 and **P < 0.01 vs. Control group; †P < 0.05 and ‡P < 0.01 vs. db/db group. Mice in each group, n = 6.
Fig. 1 (See legend on next page.)
The highest score of zinc fluorescence staining was detected in hZnT8 group (Fig. 3c). The fluorescent intensity in HG/ZnT8 RNAi group was weakest (Fig. 3f). HG treatment in NRK-52E cells for 48 h led to cell morphological changes to a fibroblast-like shape (Fig. 4b–d above). Meanwhile, expression of Vimentin was up-regulated (Fig. 4f–h above), while E-cadherin was down-regulated (Fig. 4j–i above), whereas this HG-induced EMT can be attenuated by over-expressing ZnT8 in NRK-52E cells. The protein expression of Vimentin and E-cadherin analysis by Western blot represented under the conditions of control, neo, scrambled, ZnT8 RNAi, hZnT8, HG, HG plus hZnT8 or ZnT8 RNAi, respectively. The results suggested that ZnT8 expression is associated with HG-induced EMT in a way that over-expressing ZnT8 in NRK-52E cells significantly decreased HG-induced EMT, as evidenced by the reduced up-regulation of Vimentin and ameliorated expression of E-cadherin (Fig. 4a–c below).

**Effects of ZnT8 on HG-induced TGF-β1/Smad pathway**

TGF-β1/Smad pathway plays an important role in the pathogenesis of ECM accumulation in DKD. In the current study, the protein levels of TGF-β1, p-Smad2 and p-Smad3 were found to be significantly increased in HG-exposed NRK-52E cells (Fig. 5a, d). Therefore, transfected overexpressed or knockdown ZnT8 gene was applied to determine if ZnT8-mediated protection against HG-induced EMT by inhibition of TGF-β1/Smad pathway. After transfection of ZnT8 siRNA or hZnT8-EGFP into NRK-52E cells, we performed in vivo experiments to investigate the effects of ZnT8 on EMT-tubulointerstitial fibrosis. The findings mainly include: first, expression level of EMT marker Vimentin was increased and E-cadherin decreased in HG-stimulated NRK-52E cells. The protein expression of Vimentin and E-cadherin was calculated and normalized to the loading controls. The experiments were repeated for three times (***P < 0.001 vs. Control mice and **P < 0.001 vs. STZ-induced diabetic mice).

(Fig. 3). By using ZnT8-KO, STZ-induced, db/db, ZnT8-KO-STZ and ZnT8-KO-db/db mice and NRK-52E cells, we have performed in vivo and in vitro experiments to investigate the effects of ZnT8 on EMT-tubulointerstitial fibrosis. The findings mainly include: first, expression level of EMT marker Vimentin was increased and E-cadherin decreased in HG-induced diabetes in NRK-52E cells. Therefore, data from the current study may suggest that ZnT8 have the similar effects on EMT-tubulointerstitial fibrosis in animal models for both T1DM, while db/db mouse is an animal model for T2DM. In the current study, we have studied with both animal models. Importantly, we have generated ZnT8-KO-STZ and ZnT8-KO-db/db mice, which exhibit significant increase in fasting blood glucose and albuminuria compared to diabetic animals. Furthermore, double-immunofluorescence staining and Western blot analyses indicate that EMT-tubulointerstitial fibrosis is higher in ZnT8-KO-STZ and ZnT8-KO-db/db mice than what in STZ and db/db mice. Therefore, data from the current study may suggest that ZnT8 have the similar effects on EMT-tubulointerstitial fibrosis in animal models for both T1DM and T2DM.
Fig. 2 (See legend on next page.)

A. Intensity of APQ1 and Vimentin

B. Intensity of APQ1 and E-cadherin

C. Western blot analyses of Vimentin and E-cadherin

- a. Western blot
- b. Vimentin/GAPDH
- c. E-cadherin/GAPDH
T1DM and T2DM. It is indeed important to investigate the location of expressed ZnT8 in kidney tissues. The glomerulus, particularly the mesangium, has been the focus of intense investigation in diabetes and DKD. Tubulointerstitial injury, however, is also a major feature of DKD and an important predictor of renal dysfunction. Continued exploration into tubulointerstitial disease in addition to glomerular injury in diabetes may help provide further insights into the pathogenesis of DKD and additional targets for therapeutic intervention. In the present study, we carried out the experiments and data implicated that ZnT8 was mainly expressed in renal epithelial tubular cells but very weakly in glomerulus or podocyte (please see Supplementary Fig. 2). However, the resolution of the images was not high due to the limitation of immunofluorescence staining technique. Therefore, it is necessary to ascertain the location of ZnT8 in kidneys with higher resolution technique such as the micro-dissection.

EMT plays an important role in tubulointerstitial fibrosis, which is a hallmark of DKD and identification of the mechanisms of EMT activation and targeted to reverse will be informative for understanding the pathogenesis of DKD. One hand, acute cytokine exposure of cellular models...
pancreatic β-cells reduced ZnT8 expression and intracellular labile zinc, impairing β-cell function. On another hand, there is a close relationship between downregulation of zinc transporter expression, zinc homeostasis and inflammatory response, which may contribute to the development of diabetes and DKD. A previous study has demonstrated that inflammation or TNF-α-induced protein-3 dysfunction may be involved in the pathogenesis of diabetes via ZnT8 expression, besides from pancreatic islet cell apoptosis, in which protects ZnT8 against pro-inflammatory cytokine-induced downregulation. Evidence that TGF-β1 plays significant role in EMT of renal epithelial cells, so we as to focus on the TGF-β1 in effect of ZnT8 on EMT of renal epithelial cells. In the current study, we demonstrated that inflammation factors, including IL-6, TNF and TGF-β1 in serum samples of ZnT8-KO-STZ and ZnT8-KO-db/db mice were significantly increased, which suggested that these inflammation factors together with ZnT8 dysfunction may play an important role in the progression of DKD. ZnT8 overexpression with hZnT-8-pDNA3.1/myc-hisA transfection and siRNAs targeting ZnT-8 were used in NRK52-E cells. First, we found knockdown of ZnT8 by siRNAs significantly increased the level of TGF-β1.
Conversely, overexpression of ZnT-8 decreased the TGF-β1 level. In addition, results also suggest that ZnT8 expression is associated with HG-induced EMT in a way that over-expressing ZnT8 in NRK-52E cells significantly decreased HG-induced EMT, as evidenced by the reduced up-regulation of vimentin and ameliorated expression of E-cadherin. Furthermore, we also found that the intracellular zinc accumulation was decreased after knockdown of ZnT-8 while overexpression of ZnT8 increased in intracellular zinc accumulation which followed by reversed HG-induced EMT. These data may provide further evidence of a role for the intracellular Zn2⁺ contributing to Zn2⁺ inhibit the TGF-β1 and EMT though ZnT8 mediated.

TGF-β1 plays significant role in EMT of renal epithelial cells and the activation its downstream TGF-β1/Smad signaling is required in TGF-β1-induced EMT in human proximal tubular epithelial cells. When TGF-β binds to its receptor TGF-βR1, Smad2/3 is phosphorylated and binds with Smad4, followed by translocation into the nucleus, where these complexes activate the transcription of pro-fibrotic genes. Smad4, a TGF-β signal mediator, is required for the occurrence and maintenance of EMT and in renal fibrosis, inactivation or decreased expression of Smad4 is frequently observed. Previous study showed that N6-(2-Hydroxyethyl) adenosine decreased lipopolysaccharide-induced inflammatory cytokine level in rat renal fibroblast cells and TGF-β1-induced fibroblast activation in NRK-49F cells by modulating NF-KB and TGF-β1/Smad signaling. Other study demonstrated that Tisp40 plays a critical role in the TGF-β/Smads pathway involved in this process. Hence, Tisp40 could be a useful therapeutic target in the fight against renal tubulointerstitial fibrosis. Recently, we have reported that ZnT7 has a protective effect over EMT of tubular epithelial cells under HG condition and suggests that the inhibition of HG-induced EMT may be achieved through TGF-β/Smad pathway. Because the TGF-β signaling pathway plays a central role in tubulointerstitial fibrosis, so we next investigated...
whether ZnT8 affected TGF-β pathway activity. To further explore the role of ZnT8 in EMT of tubular epithelial cells, in the current study, we have focused on the classic pro-fibrotic TGF-β signaling pathway. We found that knockdown of ZnT8 with siRNAs protocol significantly increased the luciferase activity of the Smad2 and 3. Conversely, overexpression of ZnT8 decreased the Smad2 and 3 activity. Inhibition of TGF-β1/Smad signaling activation by its specific inhibitor abrogated HG-induced activation of Smad2 and 3.

In conclusion, the current study for the first time demonstrates that ZnT8 has the protective effects against EMT-tubulointerstitial fibrosis though the restrain of TGF-β1/Smads signaling activation, which may provide a potential novel strategy for the prevention and treatment of EMT-tubulointerstitial fibrosis in DKD.

**Material and methods**

**Animals and kidney tissue preparation**

The animals used in the current study included control (C57BL/6J), ZnT8-KO, STZ-induced and ZnT8-KO-STZ mice in the first part of experiments and control, ZnT8-KO, db/db and ZnT8-KO-db/db mice in the second part of experiments. C57BL/6J male mice at 6 weeks were purchased from the Experimental Animal Center, China Medical University (Shenyang, China). Both C57BL/6N and C57BL/6J are derived from the same parental C57BL/6 strain, there are key genotypic and phenotypic differences between these two substrains. The C57BL/6J was the first and most extensively sequenced mouse genome. Therefore, large amounts of genetic and metabolic data have been generated using 6J39,40. The mice at 8 weeks of age were administered with STZ (150 mg/kg; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) diluted in 0.1 M citrate buffer (pH 4.5) as described previously41. The mice at 8 weeks serving as vehicle controls were given by intraperitoneal injection of the same volume of sodium citrate. Blood glucose levels for all mice were measured using an Accu-chek glucometer (Roche Diagnostics, Basel, Switzerland), while the mice with blood glucose >16 mmol/l were considered as diabetic one. At the time of sacrifice after injection STZ for 16 weeks, 24-h urines were collected in the metabolic cages. ZnT8-KO (C57BL/6J) male mice at 12 weeks of age were obtained from GenOway, France. db/db (C57BL/KS. Cg-Leprdb) mice at 8 weeks of age were purchased from Model Animal Research Center of Nanjing University (MARC, Nanjing, China). ZnT8-KO male mice were subsequently intercrossed with female STZ-induced or db/db mice to generate ZnT8-KO-STZ and ZnT8-KO-db/db mice, respectively. All mice were housed in plastic cages with a controlled environment (22–25 °C; 50% humidity; and 12-h light/dark cycle) and had free access to food and distilled water. These animal models were generally considered to be used for study of diabetes and DKD42.
The mice used for experiments were terminally anesthetized with sodium pentobarbital (4%; Merck Millipore) and perfused with isotonic saline, followed by 4% paraformaldehyde in 0.1 M PBS (pH 7.4). The kidneys were removed and post-fixed with 4% paraformaldehyde overnight at 4 °C for use in immunofluorescent analysis and decapitated for Western blot analysis, respectively. The experimental procedures with mice were carried out by following the rules for experimental animals at China Medical University and in accordance with the criteria described in the NIH Guide for the Care and Use of Laboratory Animals. The IRB numbers are 201401112 and 201712020.

Measurement of serum and urine parameters

Blood glucose levels were measured using an Accu-chek glucometer (Roche Diagnostics, Basel, Switzerland). The levels of blood urea nitrogen (BUN), serum creatinine (Scr) and micro-albumin were measured using the automated chemistry analyzer (Hitachi 917, Tokyo, Japan) and the commercial kits (Wako, Osaka, Japan).

Enzyme-linked immunosorbent assay

To assess inflammation markers, serum samples were analyzed using mouse Magnetic Luminex Screening assays containing a premixed multi-analyte kit for murine TGF-β, TNF-α and IL-6 (R&D Systems, Minneapolis, MN, USA) on a Luminex 200 (Austin, TX, USA). The color generated was determined by measuring the optical density value at 450 nm with a spectrophotometric microtiter plate reader (Molecular Devices Corp., Sunnyvale, CA, USA).

Cell culture

Normal rat kidney tubular epithelial cell line (NRK-52E) was obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) as previously described. In the control group, the cells were treated with serum free DMEM medium only. In HG group, the cells were treated with 30 mM HG for 12, 24, 48, 72, and 96 h. The scrambled siRNA sequence in mZnT8 mRNA, 5′-UUCUCCGAACGUUGACGUAGUGCUUUATT-3′. Cells were transfected with plasmid or siRNA using Lipofectamine 2000 (Life Technologies, USA) according to the manufacturer’s protocol. Western-blot analysis was performed to help optimize exogenous expression and RNAi silencing of ZnT8 with transfection.

Assessment of cell viability

Cell viability was measured by quantitative colorimetric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in 96-well plates. Briefly, at the indicated time after treatment, 10 μl MTT (final concentration, 500 μg/mL) was added to the medium and incubated at 37 °C for 3 h. The MTT solution was removed and 100 μl dimethyl sulfoxide (DMSO) was added to dissolve the colored formazan crystals for 15 min. The absorbance at 490 nm of each aliquot was measured using a Sunrise RC microplate reader (TECAN, Männedorf, Switzerland). Cell viability was expressed as the ratio of the signal obtained from treated cultures and control cultures.

Immunofluorescence staining

Kidney tissues were anesthetized deeply with sodium pentobarbital and perfused with isotonic saline, followed by 4% paraformaldehyde in 0.1 M of phosphate buffered saline (PBS; pH 7.4). The kidney was removed and post-fixed with 4% paraformaldehyde overnight at 4 °C. Serial paraffin sections (4 μm) were prepared, dewaxed in xylene, and rehydrated using gradient alcohol solutions. The cryostat sections were then pre-incubated with normal donkey serum (1:20) for 1 h and incubated overnight at room temperature with anti-aquaporin-1 (polyclonal antibody, Abcam ab232399) at 1:100 and anti- E-cadherin (polyclonal antibody, Abcam ab1416) at 1:100; anti-Vimentin (polyclonal antibody, Abcam ab128507) at 1:100. After rinsing with PBS, the sections were incubated for 2 h with DAR-FITC (1:50) and Texas Red-DAM (1:50, Jackson ImmunoResearch) at RT. The sections were mounted and examined in a confocal laser scanning microscope (CLSM, SP2, Leica, Germany).

NRK-52E cells were fixed in 4% paraformaldehyde and per-mobilized in 0.1% Triton X-100, before they were respectively treated with primary mouse monoclonal anti- E-cadherin (E-ca) antibody (1:100, polyclonal antibody, Abcam ab1416), mouse monoclonal Vimentin antibody (1:100) and the sections were incubated for 2 h with DAR-FITC (1:50) and Texas Red-DAM (1:50) at RT. The fluorescent images were visualized with a Fluoview 300 fluorescence microscope (Olympus, Tokyo, Japan).

Western blot analysis

Western blot analysis was performed as previously described. Kidney tissues were homogenized in cold...
radio-immunoprecipitation assay lysis buffer, incubated on ice for 1 h, centrifuged at 12,000 x g for 20 min at 4 °C and then the supernatants were transferred to a clean tube. Protein concentrations were quantified using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Briefly, equal amounts of protein samples from kidney cortex fragments or NRK-52E cells were subjected to SDS-PAGE using 10% gradient Tris/glycine gels. Then, the proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Temecula, CA, USA). After blocking with 5% fat-free milk for 1 h, the blots were incubated with the following primary antibodies. The primary antibodies used in the present study were as follows: rabbit anti-ZnT8 (Mellitech, 1:200), Goat polyclonal anti-Vimentin (1:400, Abcam ab8978), mouse monoclonal anti-E-cad (1:400, Abcam ab1416), and mouse monoclonal anti-GAPDH (1:400; Santa Cruz Biotechnology, Inc., Shanghai, China). Following development, the band intensities were quantified using Image-Pro plus 6.0 analysis software (Media Cybernetics, Inc., Rockville, MD, USA). The blots were repeated at least three times for each condition.

Zinc analysis
N-(6-methoxy-8-quinolyl)-p-toluenesulfonamide (TSQ) is a one-step staining procedure and by the stoichiometric formation of zinc. To analyze the distribution and concentration of zinc in the cells, TSQ fluorescence staining was analyzed as described previously. Cultured NRK-52E cells were immersed in a solution of 4.5 μM TSQ (Molecular Probes, Eugene, USA) in 140 mM sodium barbital and 140 mM sodium acetate buffer (pH 10.5) for 1 min. TSQ binding was imaged with a fluorescence microscope.

Statistical analysis
Statistical analysis was performed using SPSS (Version 18, IBM Corporation, Armonk, NY, USA). Data were expressed as means ± standard error (SEM). Variance was homogenous for use of standard ANOVA methodology. Individual comparisons were made using Tukey’s multiple comparison tests after statistical significance was established by ANOVA. P < 0.05 was considered as significance.

Acknowledgements
This work was supported by grants from the Natural Science Foundation of China (81670670), Shenzhen Key Medical Discipline Construction Fund and Postdoctoral Science Foundation of China (2014M551144).

Author details
1Department of Nephrology, Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, 518000 Shenzhen, Guangdong Province, P.R. China. 2Department of Pathophysiology, China Medical University, 110001 Shenyang, Liaoning Province, P.R. China. 3Center for Pathophysiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 210009 Nanjing, Jiangsu Province, P.R. China.

Author contributions
X.Z.: study concept and design, data acquisition, data analysis and paper preparation; T.G., B.Y.: Data acquisition; H.F.Gu.: supervision, data interpretation, paper revision and finalization; Z.C.: experimental design, data interpretation and paper revision. All authors approved the final version of paper.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supporting information
Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-020-2751-6).

Received: 26 February 2020 Revised: 21 June 2020 Accepted: 25 June 2020
Published online: 17 July 2020

References
1. Barrett, E. J. et al. Diabetic microvascular disease: an endocrine society scientific statement. J. Clin. Endocrinol. Metab. 102(Suppl. 12), 4343–4410 (2017).
2. Thomas, M. C. et al. Diabetic kidney disease. Nat. Rev. Dis. Prim. 1, 15018 (2015).
3. Doshi, S. M. & Friedman, A. N. Diagnosis and management of Type 2 diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 12, 1366–1373 (2017).
4. Bouharne, V. E. & McGill, J. B. Diabetic kidney disease. Mol. Med. 113, 390–394 (2016).
5. Simonson, M. S. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int. 71, 846–854 (2007).
6. Gilbert, R. E. & Cooper, M. E. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 56, 1627–1637 (1999).
7. Maciasac, R. J., Binci, E. J. & Jerums, G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am. J. Kidney Dis. 63, 539–62 (2014).
8. Pichler, R., Alkanian, M., Dieter, B. P. & Tuttle, K. R. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am. J. Physiol. Ren. Physiol. 312(Suppl. 4), F716–F731 (2017).
9. Navarro-González, J. F., Mora-Fernández, C., Muros de Fuentes, M. & García-Pérez, I. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7(Suppl. 6), 327–340 (2011).
10. Shikano, M. et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85(Suppl. 1), 81–85 (2000).
11. Skupien, J. et al. Synergism between circulating tumor necrosis factor receptor 2 and HbA1c in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabetes Care 37(Suppl. 9), 2601–2608 (2014).
2. Seman, N. A. et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. *Nat. Med.* **25**(Suppl. 5), 805–813 (2019).

3. Kambé, T., Yamaguchi-Iwa, Y., Sasaki, R. & Nagao, M. Overview of mammalian zinc transporters. *Cell Mol. Life Sci.* **61**(Suppl. 1), 49–68 (2004).

4. Kambé, T., Tsuj, T., Hashimoto, A. & Itsumura, N. The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. *Physiol. Rev.* **95**(Suppl. 3), 749–784 (2015).

5. Zhang, X. et al. A novel role for zinc transporter 8 in the facilitation of zinc accumulation and regulation of testosterone synthesis in Leydig cells of human and mouse testicles. *Mol. Endocrinol.* **28**, 40–50 (2018).

6. Gu, H. F. Genetic, epigenetic and biological effects of zinc transporter (SLC30A8) in Type 1 and Type 2 diabetes. *Curr. Diabetes Rev.* **13**(Suppl. 2), 132–140 (2017).

7. Wendau, J. M. et al. Novel antigens in type 1 diabetes: the importance of ZnT8. *Curr. Diabet Rep.* **9**(Suppl. 2), 105–112 (2009).

8. Chimenti, F., Favier, A. & Seve, M. ZnT-8, a pancreatic beta-cell-specific zinc transporter. *Biometals* **18**(Suppl. 4), 313–317 (2005).

9. Williams, C. L. & Long, A. E. What has zinc transporter 8 autoimmunity taught us about type 1 diabetes? *Diabetologia* **62**(Suppl. 11), 1969–1976 (2019).

10. Strawbridge, R. J. et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes* **60**(Suppl. 10), 2624–2634 (2011).

11. Flannick, J. et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. *Nat. Genet.* **46**(Suppl. 4), 357–363 (2014).

12. Seman, N. A., Mohamud, W. N., Östenson, C. G., Brismar, K. & Gu, H. F. Increased DNA methylation of the SLC30A8 gene promoter is associated with type 2 diabetes in a Malay population. *Clin. Epigenetics* **7**(Suppl. 1), 30 (2015).

13. Deniro, M. & Al-Mohanna, F. A. Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. *PLoS ONE* **7**(Suppl. 11), e50360 (2012).

14. Pirina, A. et al. Detection of serum antibodies cross-reacting with Mycobacterium avium subspecies paratuberculosis and beta-cell antigen zinc transporter 8 homologous peptides in patients with high-risk proliferative diabetic retinopathy. *PLoS ONE* **9**(Suppl. 9), e107802 (2014).

15. Xu, G. et al. Erythropoietin protects renal cells in diabetic rats through upregulating ZnT8 via activating ERK pathway and inhibiting HIF-1α expression. *Invest Ophthalmol. Vis. Sci.* **56**(Suppl. 13), 8166–8178 (2015).

16. Vizza, D. et al. Nerve growth factor exposure promotes tubular epithelial-mesenchymal transition via TGF-β1 signaling activation. *Growth Factors* **33** (Suppl. 3), 169–180 (2015).

17. Mitchell, R. K. et al. Molecular genetic regulation of Slc30a8/ZnT8 reveals a positive association with glucose tolerance. *Mol. Endocrinol.* **30**(Suppl. 1), 77–91 (2016).

18. Nicolson, T. J. et al. Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. *Diabetes* **58**(Suppl. 9), 2070–2083 (2009).

19. Chimenti, F., Devengras, S., Favier, A. & Seve, M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT8, localized into insulin secretory granules. *Diabetes* **53**(Suppl. 9), 2330–2337 (2004).

20. Hardy, A. B. et al. Effects of high-fat diet feeding on Znt8-null mice: differences between β-cell and global knockout of ZnT8. *Am. J. Physiol. Endocrinol. Metab.* **302**(Suppl. 9), E1064–E1096 (2012).

21. Gilbert, R. E. & Cooper, M. E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? *Kidney Int.* **56**(Suppl. 5), 1627–1637 (1999).

22. Zhang, X. et al. Protective effect of ZnT8 on high glucose-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells. *Kidney Blood Press Res.* **43**(Suppl. 2), 500–512 (2018).

23. El Mualjed, M. et al. Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic beta-cell function. *J. Endocrinol.* **206**, 159–169 (2010).

24. Cheng, L., Zhang, D. & Chen, B. Tumor necrosis factor α-induced protein-3 protects zinc transporter 8 against proinflammatory cytokine-induced downregulation. *Exp. Ther. Med.* **12**(Suppl. 3), 1509–1514 (2016).

25. Zheng, R. et al. N6-(2-Hydroxyethyl) adenosine from cordyceps cicadae ameliorates renal interstitial fibrosis and prevents inflammation via TGF-β1/Smad and NF-κB signaling pathway. *Front Physiol.* **9**, 1229 (2018).

26. Xiao, C. C. et al. Identification of Tisp40 as an essential regulator of renal tubulointerstitial fibrosis via TGF-β/Smad signaling pathway. *Cell Physiol. Biochem* **42**(2), 697–712 (2017).

27. Zhang et al. Mouse Genome Sequencing Consortium, Initial sequencing and comparative analysis of the mouse genome. *Nature* **420**(Suppl. 6915), 520–562 (2002).

28. Fontaine, D. A. & Davis, D. B. Attention to background strain is essential for metabolic research: CS7BL/6 and the International Knockout Mouse Consortium. *Diabetes* **65**(Suppl. 1), 25–33 (2016).

29. Tesch, G. H. & Allen, T. J. Rodent models of streptozotocin-induced diabetic nephropathy. *Nephrol. (Carlton)* **32**(Suppl. 3), 261–266 (2007).

30. Kitada, M., Ogura, Y. & Koya, D. Rodent models of diabetic nephropathy: their utility and limitations. *Int J. Nephrol. Renovas. Dis.* **9**, 279–290 (2016).

31. Huang, C., Wang, X. L., Qi, F. F. & Pang, Z. L. Berberine inhibits epithelial-mesenchymal transition and promotes apoptosis of tumour-associated fibroblast-induced colonic epithelial cells through regulation of TGF-β signaling. *J. Cell Commun. Signal* **14**(Suppl. 1), 53–66 (2020).

32. Frederickson, C. J., Kasarskis, E. J., Ringo, D. & Frederickson, R. E. A quinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain. *J. Neurosci. Methods* **20**(Suppl. 2), 91–103 (1987).